244 related articles for article (PubMed ID: 26567444)
1. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.
Samuel P; Pink RC; Brooks SA; Carter DR
Expert Rev Anticancer Ther; 2016; 16(1):57-70. PubMed ID: 26567444
[TBL] [Abstract][Full Text] [Related]
2. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
3. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
5. [The mechanism of cisplatin-resistance in ovarian cancer].
Kikuchi Y
Hum Cell; 2001 Jun; 14(2):115-33. PubMed ID: 11552292
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
8. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
9. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
Echevarría-Vargas IM; Valiyeva F; Vivas-Mejía PE
PLoS One; 2014; 9(5):e97094. PubMed ID: 24865582
[TBL] [Abstract][Full Text] [Related]
11. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract][Full Text] [Related]
13. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
14. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.
Fu X; Tian J; Zhang L; Chen Y; Hao Q
FEBS Lett; 2012 May; 586(9):1279-86. PubMed ID: 22465665
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
17. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
Boac BM; Xiong Y; Marchion DC; Abbasi F; Bush SH; Ramirez IJ; Khulpateea BR; Clair McClung E; Berry AL; Bou Zgheib N; Chon HS; Shahzad MM; Judson PL; Wenham RM; Apte SM; Berglund AE; Magliocco AM; Lancaster JM
Gynecol Oncol; 2016 Feb; 140(2):259-63. PubMed ID: 26731723
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
19. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]